Rate My Professor Tony de Soyza

De Soyza's research specializations encompass pulmonary infections, their consequences, and management, particularly Gram-negative infections in cystic fibrosis, bronchiectasis, and severe COPD. Key interests include lipopolysaccharide biological activity, inflammatory pathways and biomarkers, airway microbiome, bacteriophages, prognostic indices, and lung inflammaging. His contributions extend to COVID-19 research, including local lead for the RECOVERY trial and PHOS-COVID working group. Awards include the 3M Pharmaceuticals Small Airways Research Prize in 1999, University of Newcastle School of Medicine Annual Research Presentation First Prize in 2000, Wellcome Trust Clinical Training Fellowship from 2001 to 2003, British Lung Foundation Young Investigator of the Year in 2003, one of two national HECFE award winners in Respiratory Medicine in 2007, and Vice-Chair of multinational COST action BM1003 in Cystic Fibrosis pathogens from 2010 to 2014. Notable publications comprise 'Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis' (Chalmers JD et al., New England Journal of Medicine, 2025), 'Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis' (Sibila O et al., The Lancet Respiratory Medicine, 2025), 'European Respiratory Society guidelines for the management of adult bronchiectasis' (Polverino E et al., 2017), 'Anxiety, depression, physical disease parameters and health-related quality of life in the BronchUK national bronchiectasis cohort' (De Soyza A et al., ERJ Open Research, 2025), and 'Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT' (Devereux G et al., Health Technology Assessment, 2025). His work has advanced clinical trials, registries, and guidelines, influencing respiratory medicine globally through high-impact journals and leadership in multinational consortia.